Vaccines and Related Biological Products Advisory Committee; Notice of Meeting, 3639 [2011-1105]
Download as PDF
<![CDATA[
Federal Register / Vol. 76, No. 13 / Thursday, January 20, 2011 / Notices
the Healthy Living Innovation Awards
on behalf of the HHS. Nominations can
only be made electronically at https://
HealthyLivingInnovation.Challenge.gov.
The
Department of Health and Human
Services is the U.S. government’s
principal agency for promoting and
protecting the health of all Americans.
The HHS manages many programs,
covering a broad spectrum of health
promotion and disease prevention
services and activities. Leaders in the
business community, State and local
government officials, tribes and tribal
entities, and charitable, faith-based, and
community organizations have
expressed an interest in working with
the Department to promote healthy
choices and behaviors. The Secretary
welcomes this interest. With this notice,
the Secretary outlines opportunities to
identify and celebrate outstanding
organizations that have implemented
innovative and creative health
promotion programs.
SUPPLEMENTARY INFORMATION:
Dated: January 14, 2011.
Sherry Glied,
Assistant Secretary for Planning and
Evaluation.
[FR Doc. 2011–1180 Filed 1–19–11; 8:45 am]
BILLING CODE 4150–05–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2010–N–0001]
Vaccines and Related Biological
Products Advisory Committee; Notice
of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
mstockstill on DSKH9S0YB1PROD with NOTICES
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: Vaccines and Related
Biological Products Advisory Committee.
General Function of the Committee: To
provide advice and recommendations to the
Agency on FDA’s regulatory issues.
Date and Time: The meeting will be held
on February 25, 2011, between
approximately 8:30 a.m. and 1:50 p.m.
Location: DoubleTree Hotel Bethesda and
Executive Meeting Center, 8120 Wisconsin
Ave., Bethesda, MD 20814.
Contact Person: Donald W. Jehn or Denise
Royster, Center for Biologics Evaluation and
Research (HFM–71), Food and Drug
Administration, 1401 Rockville Pike,
Rockville, MD 20852, 301–827–0314, or FDA
VerDate Mar<15>2010
18:24 Jan 19, 2011
Jkt 223001
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington, DC area), and follow the
prompts to the desired center or product
area. Please call the Information Line for upto-date information on this meeting. A notice
in the Federal Register about last minute
modifications that impact a previously
announced advisory committee meeting
cannot always be published quickly enough
to provide timely notice. Therefore, you
should always check the Agency’s Web site
and call the appropriate advisory committee
hot line/phone line to learn about possible
modifications before coming to the meeting.
Agenda: On February 25, 2011, the
committee will discuss and make
recommendations on the selection of strains
to be included in the influenza virus vaccine
for the 2011–2012 influenza season. The
committee will also hear an update on
Pandemic Influenza Surveillance.
FDA intends to make background material
available to the public no later than 2
business days before the meeting. If FDA is
unable to post the background material on its
Web site prior to the meeting, the background
material will be made publicly available at
the location of the advisory committee
meeting, and the background material will be
posted on FDA’s Web site after the meeting.
Background material is available at https://
www.fda.gov/AdvisoryCommittees/Calendar/
default.htm. Scroll down to the appropriate
advisory committee link.
Procedure: Interested persons may present
data, information, or views, orally or in
writing, on issues pending before the
committee. Written submissions may be
made to the contact person on or before
February 18, 2011. Oral presentations from
the public will be scheduled between
approximately 11:50 a.m. and 12:50 p.m.
Those individuals interested in making
formal oral presentations should notify the
contact person and submit a brief statement
of the general nature of the evidence or
arguments they wish to present, the names
and addresses of proposed participants, and
an indication of the approximate time
requested to make their presentation on or
before February 10, 2011. Time allotted for
each presentation may be limited. If the
number of registrants requesting to speak is
greater than can be reasonably
accommodated during the scheduled open
public hearing session, FDA may conduct a
lottery to determine the speakers for the
scheduled open public hearing session. The
contact person will notify interested persons
regarding their request to speak by February
11, 2011.
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee meetings
and will make every effort to accommodate
persons with physical disabilities or special
needs. If you require special accommodations
due to a disability, please contact Donald W.
Jehn or Denise Royster at least 7 days in
advance of the meeting.
FDA is committed to the orderly conduct
of its advisory committee meetings. Please
PO 00000
Frm 00041
Fmt 4703
Sfmt 9990
3639
visit our Web site at https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/ucm111462.htm
for procedures on public conduct during
advisory committee meetings.
Notice of this meeting is given under the
Federal Advisory Committee Act (5 U.S.C.
app. 2).
Dated: January 12, 2011.
Jill Hartzler Warner,
Acting Associate Commissioner for Special
Medical Programs.
[FR Doc. 2011–1105 Filed 1–19–11; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
National Advisory Council on the
National Health Service Corps; Notice
of Meeting
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), notice is hereby given
of the following meeting:
Name: National Advisory Council on the
National Health Service Corps (NHSC).
Dates and Times: February 10, 2011—1
p.m.–4 p.m.; February 11, 2011—8:30 a.m.–
4 p.m.
Place: Bethesda North Marriott Hotel &
Conference Center, 5701 Marinelli Road,
Bethesda, MD 20852, Phone: 301–822–9200.
Status: The meeting will be open to the
public.
Agenda: The Council is convening in
Bethesda, MD to hear NHSC program
updates. Findings from recent research will
be discussed along with future plans for
additional research. Site Partnerships,
Clinician Retention and NHSC
Communications and Marketing Strategies
will also be part of the discussions.
For Further Information Contact: Njeri
Jones, Bureau of Clinician Recruitment and
Service, Health Resources and Services
Administration, Parklawn Building, Room
8A–46, 5600 Fishers Lane, Rockville, MD
20857; e-mail: NJones@hrsa.gov; Telephone:
301–443–2541.
Dated: January 12, 2011.
Robert Hendricks,
Director, Division of Policy and Information
Coordination.
[FR Doc. 2011–1112 Filed 1–19–11; 8:45 am]
BILLING CODE 4165–15–P
E:\FR\FM\20JAN1.SGM
20JAN1
]]>Agencies
[Federal Register Volume 76, Number 13 (Thursday, January 20, 2011)]
[Notices]
[Page 3639]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-1105]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2010-N-0001]
Vaccines and Related Biological Products Advisory Committee;
Notice of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
This notice announces a forthcoming meeting of a public advisory
committee of the Food and Drug Administration (FDA). The meeting will
be open to the public.
Name of Committee: Vaccines and Related Biological Products
Advisory Committee.
General Function of the Committee: To provide advice and
recommendations to the Agency on FDA's regulatory issues.
Date and Time: The meeting will be held on February 25, 2011,
between approximately 8:30 a.m. and 1:50 p.m.
Location: DoubleTree Hotel Bethesda and Executive Meeting
Center, 8120 Wisconsin Ave., Bethesda, MD 20814.
Contact Person: Donald W. Jehn or Denise Royster, Center for
Biologics Evaluation and Research (HFM-71), Food and Drug
Administration, 1401 Rockville Pike, Rockville, MD 20852, 301-827-
0314, or FDA Advisory Committee Information Line, 1-800-741-8138
(301-443-0572 in the Washington, DC area), and follow the prompts to
the desired center or product area. Please call the Information Line
for up-to-date information on this meeting. A notice in the Federal
Register about last minute modifications that impact a previously
announced advisory committee meeting cannot always be published
quickly enough to provide timely notice. Therefore, you should
always check the Agency's Web site and call the appropriate advisory
committee hot line/phone line to learn about possible modifications
before coming to the meeting.
Agenda: On February 25, 2011, the committee will discuss and
make recommendations on the selection of strains to be included in
the influenza virus vaccine for the 2011-2012 influenza season. The
committee will also hear an update on Pandemic Influenza
Surveillance.
FDA intends to make background material available to the public
no later than 2 business days before the meeting. If FDA is unable
to post the background material on its Web site prior to the
meeting, the background material will be made publicly available at
the location of the advisory committee meeting, and the background
material will be posted on FDA's Web site after the meeting.
Background material is available at https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the
appropriate advisory committee link.
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person on or before
February 18, 2011. Oral presentations from the public will be
scheduled between approximately 11:50 a.m. and 12:50 p.m. Those
individuals interested in making formal oral presentations should
notify the contact person and submit a brief statement of the
general nature of the evidence or arguments they wish to present,
the names and addresses of proposed participants, and an indication
of the approximate time requested to make their presentation on or
before February 10, 2011. Time allotted for each presentation may be
limited. If the number of registrants requesting to speak is greater
than can be reasonably accommodated during the scheduled open public
hearing session, FDA may conduct a lottery to determine the speakers
for the scheduled open public hearing session. The contact person
will notify interested persons regarding their request to speak by
February 11, 2011.
Persons attending FDA's advisory committee meetings are advised
that the Agency is not responsible for providing access to
electrical outlets.
FDA welcomes the attendance of the public at its advisory
committee meetings and will make every effort to accommodate persons
with physical disabilities or special needs. If you require special
accommodations due to a disability, please contact Donald W. Jehn or
Denise Royster at least 7 days in advance of the meeting.
FDA is committed to the orderly conduct of its advisory
committee meetings. Please visit our Web site at https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for
procedures on public conduct during advisory committee meetings.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: January 12, 2011.
Jill Hartzler Warner,
Acting Associate Commissioner for Special Medical Programs.
[FR Doc. 2011-1105 Filed 1-19-11; 8:45 am]
BILLING CODE 4160-01-P
